

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 8, 2002.

BioTime, Inc.
(Exact name of registrant as specified in its charter)

1-12830
(Commission File Number)

California
(State or other jurisdiction
of incorporation)

94-3127919
(IRS Employer
Identification No.)

935 Pardee Street
Berkeley, California 94710
(Address of principal executive offices)

(510) 845-9535
(Registrant's telephone number, including area code)

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions identify forward-looking statements.

Item 5. Other Events.

The Health Products and Food Branch, Health Canada, has approved Hextend(R) for sale in Canada. Hextend is BioTime's proprietary hetastarch-based plasma volume expander with lactate, multiple electrolytes, and physiological amounts of glucose. Hextend will be marketed in Canada by Abbott Laboratories, Limited, Canada, an affiliate of Abbott International.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date: July 9, 2002

By /s/ Paul Segall

Paul E. Segall
Chairman and Chief Executive Officer